The Trend of Urinary N Terminal Probrain Natriuretic Peptide in Extremely Low Birth Weight Infants during the Neonatal Period

Abstract

Objective N-terminal probrain natriuretic peptide (NT-proBNP) is a biomarker of interest in many cardiopulmonary diseases in extremely low birth weight (ELBW) Infants. However, there is a gap in knowledge about the trend of ELBW infant's urinary NT-proBNP during the neonatal period.

Aim To determine the trend of urinary NT-proBNP during the first 4 weeks of life of an ELBW infant.

Study Design We analyzed prospectively enrolled 87 ELBW infants. Urinary NT-proBNP to creatinine ratios were measured on days 1 to 7, 14, and 28 of life. We plotted each study point's means to determine the trend of urinary NT-proBNP over the entire neonatal period. Data were analyzed using the Friedman analysis of variance for comparative analysis of study points.

Results Urinary NT-proBNP/creatinine ratios were significantly elevated on days 1 to 7 (mean 2,452, ± 1,518) than day 14 (mean 747, ± 176), and day 28 (mean 149, ± 54), p = 0.001. Overall, urinary NT-proBNP levels were highest during days 1 to 3 (mean 3,232, ± 1,255) and lowest on day 28 (mean 149, ± 54).

Conclusion Urinary NT-proBNP levels are higher during the first week in ELBW infants with a downward trend during the neonatal period, the lowest values at 4 weeks postnatal age. More studies are required to determine the clinical utility of this trend during and beyond the neonatal period.

Key Points

• NT-proBNP is a biomarker for monitoring cardiac disease in premature infants.

• The trend of urinary NT-proBNP is unknown in premature infants.

• A trend of urinary NT-proBNP was determined during the first 4 weeks in premature infants.

Keywords

NT-proBNP - trend - premature - infants

• References

• 1 El-Khuffash A, Molloy E. The use of N-terminal-pro-BNP in preterm infants. Int J Pediatr 2009; 2009: 175216
• 2 Westerlind A, Wåhlander H, Lindstedt G, Lundberg PA, Holmgren D. Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004; 93 (03) 340-345
• 3 Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006; 27 (07) 861-866
• 4 Nasser N, Perles Z, Rein AJJT, Nir A. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2006; 27 (01) 87-90
• 5 Cohen S, Springer C, Avital A. et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress?. Pediatrics 2005; 115 (05) 1347-1350
• 6 Gessler P, Knirsch W, Schmitt B, Rousson V, von Eckardstein A. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr 2006; 148 (03) 372-376
• 7 Carmona F, Manso PH, Vicente WV, Castro M, Carlotti AP. Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine 2008; 42 (03) 317-324
• 8 Shalev A, Nir A, Granot E. Cardiac function in children post-orthotopic liver transplantation: echocardiographic parameters and biochemical markers of subclinical cardiovascular damage. Pediatr Transplant 2005; 9 (06) 718-722
• 9 El-Khuffash A, Barry D, Walsh K, Davis PG, Molloy EJ. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed 2008; 93 (06) F407-F412
• 10 Nuntnarumit P, Khositseth A, Thanomsingh P. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol 2009; 29 (02) 137-142
• 11 Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008; 93 (04) F257-F260
• 12 Ramakrishnan S, Heung YM, Round J, Morris TP, Collinson P, Williams AF. Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants. Acta Paediatr 2009; 98 (08) 1254-1259
• 13 Harris SL, More K, Dixon B. et al. Factors affecting N-terminal pro-B-type natriuretic peptide levels in preterm infants and use in determination of haemodynamic significance of patent ductus arteriosus. Eur J Pediatr 2018; 177 (04) 521-532
• 14 Méndez-Abad P, Zafra-Rodríguez P, Lubián-López S, Benavente-Fernández I. NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants. Eur J Pediatr 2019; 178 (05) 755-761
• 15 Khan S, Concina VA, Schneider D, Westgate P, Arriagada S, Bada H. Role of NT-proBNP in the prediction of moderate to severe bronchopulmonary dysplasia in preterm infants. Pediatr Pulmonol 2020; 55 (02) 376-382
• 16 Montgomery AM, Bazzy-Asaad A, Asnes JD, Bizzarro MJ, Ehrenkranz RA, Weismann CG. Biochemical screening for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Neonatology 2016; 109 (03) 190-194
• 17 Akcan AB, Kardelen F, Oygucu SE. et al. The efficacy of cardiac findings in assessing the outcome in preterms with bronchopulmonary dysplasia. Indian J Pediatr 2013; 80 (11) 896-902
• 18 Rodríguez-Blanco S, Oulego-Erroz I, Alonso-Quintela P, Terroba-Seara S, Jiménez-González A, Palau-Benavides M. N-terminal-probrain natriuretic peptide as a biomarker of moderate to severe bronchopulmonary dysplasia in preterm infants: a prospective observational study. Pediatr Pulmonol 2018; 53 (08) 1073-1081
• 19 Zhou L, Xiang X, Wang L, Chen X, Zhu J, Xia H. N-terminal pro-B-type natriuretic peptide as a biomarker of bronchopulmonary dysplasia or death in preterm infants: a retrospective cohort analysis. Front Pediatr 2019; 7: 166
• 20 Joseph L, Nir A, Hammerman C, Goldberg S, Ben Shalom E, Picard E. N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am J Perinatol 2010; 27 (05) 381-386
• 21 Sellmer A, Hjortdal VE, Bjerre JV. et al. N-terminal pro-B type natriuretic peptide as a marker of bronchopulmonary dysplasia or death in very preterm neonates: a cohort study. PLoS One 2015; 10 (10) e0140079
• 22 Montaner A, Pinillos R, Galve Z. et al. Brain natriuretic propeptide as an early marker of bronchopulmonary dysplasia or death in the preterm newborn. Klin Padiatr 2017; 229 (04) 223-228
• 23 Dasgupta S, Aly AM, Malloy MH, Okorodudu AO, Jain SK. NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol 2018; 38 (09) 1252-1257
• 24 Czernik C, Metze B, Müller C, Bührer C. Urinary NT-proBNP and ductal closure in preterm infants. J Perinatol 2013; 33 (03) 212-217
• 25 Khan SS, Sithisarn T, Bada HS, Vranicar M, Westgate PM, Hanna M. Urinary NT-proBNP levels and echocardiographic parameters for patent ductus arteriosus. J Perinatol 2017; 37 (12) 1319-1324
• 26 Naeem B, Ayub A, Aly AM, Malloy MH, Okorodudu AO, Jain SK. Urinary NT-proBNP as a potential noninvasive biomarker for screening of pulmonary hypertension in preterm infants: a pilot study. J Perinatol 2020; 40 (04) 628-632
• 27 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332 (6159): 78-81
• 28 Yasue H, Yoshimura M, Sumida H. et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90 (01) 195-203
• 29 McDowell G, Shaw C, Buchanan KD, Nicholls DP. The natriuretic peptide family. Eur J Clin Invest 1995; 25 (05) 291-298
• 30 Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens 1994; 12 (04) 329-336
• 31 de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31 (01) 7-18
• 32 Yandle TG. Biochemistry of natriuretic peptides. J Intern Med 1994; 235 (06) 561-576
• 33 Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; (191) 341-366
• 34 Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38 (06) 519-523
• 35 Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta 1999; 285 (1-2): 169-172
• 36 Kemperman H, van den Berg M, Kirkels H, de Jonge N. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem 2004; 50 (09) 1670-1672
• 37 Nir A, Lindinger A, Rauh M. et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009; 30 (01) 3-8
• 38 Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89 (08) 875-878
• 39 Mir TS, Laux R, Hellwege HH. et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003; 112 (04) 896-899
• 40 Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004; 93 (05) 603-607
• 41 Yoshibayashi M, Kamiya T, Saito Y. et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995; 133 (02) 207-209
• 42 Roche Diagnostics. Elecsys proBNP II. In: PROBNP II, N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE. Roche Diagnostics; https://www.rochecanada.com/content/dam/rochexx/roche-ca/products/docs/package_inserts/ElecsysproBNPII-07027664190-EN-CAN.pdf
• 43 Czernik C, Metze B, Müller C, Müller B, Bührer C. Urinary N-terminal B-type natriuretic peptide predicts severe retinopathy of prematurity. Pediatrics 2011; 128 (03) e545-e549
• 44 Fritz AS, Keller T, Kribs A, Hünseler C. Reference values for N-terminal pro-brain natriuretic peptide in premature infants during their first weeks of life. Eur J Pediatr 2021; 180 (04) 1193-1201